Company Overview
Orion Corporation is a Finnish multinational pharmaceutical company that has been a leading player in the global healthcare industry for over 90 years. With its rich history and strong brand presence, Orion has established itself as a trusted partner for patients, healthcare professionals, and pharmaceutical companies alike.
The company's primary mission is to improve human health by developing, manufacturing, and marketing innovative medicines and medical products. Orion's core values are built around its commitment to innovation, quality, safety, and sustainability, which guide the company's decision-making and behavior.
Key Products/Services
Orion's product portfolio includes a wide range of innovative medicines and medical products for various therapeutic areas, such as oncology, neurology, and infectious diseases. Some of its key products include:
- Nubeqa (abemaciclib), an oral small-molecule inhibitor of CDK4 and CDK6, used in the treatment of certain types of cancer.
- Orfella (alfentanil), a long-acting opioid analgesic for pain management.
- Exjade (fesoterodine fumarate), an antimuscarinic agent used in the treatment of overactive bladder.
These products have been developed and manufactured using Orion's state-of-the-art technology and quality systems, ensuring their safety and efficacy for patients. Additionally, Orion offers a range of generic medicines and consumer health products, which cater to the growing demand for affordable healthcare solutions.
Benefits
Orion's innovative medicines and medical products offer several benefits to patients, healthcare professionals, and pharmaceutical companies. Some of these benefits include:
- Improved treatment options: Orion's products provide new and innovative treatments for various diseases, improving patient outcomes and quality of life.
- Increased efficiency: Orion's generic medicines and consumer health products offer affordable alternatives to branded products, increasing access to healthcare solutions.
- Enhanced research capabilities: Orion's strong R&D capabilities enable the company to develop new medicines and medical products, driving innovation in the industry.
In conclusion, Orion Corporation is a reputable pharmaceutical company that has established itself as a leader in the global healthcare industry. With its commitment to innovation, quality, safety, and sustainability, Orion offers a range of innovative medicines and medical products that improve patient outcomes and provide value to patients, healthcare professionals, and pharmaceutical companies.
Valuation
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Number of Shares (million) | 141.1 | 141.1 | 141.1 | 141.1 | 141.1 | 141.1 | 141.1 |
| Target Valuation (MEur) | 2066.9 | 2248.8 | 2978.7 | 4123.1 | 4410.6 | 5697.8 | 5697.8 |
| Targer Price | 14.65 | 15.93 | 21.11 | 29.21 | 31.25 | 40.37 | 40.37 |
| Potential, % | -71.4 | -59.4 | -50.7 | -54.1 | -60.1 | -48.5 | -48.5 |
| Recommendation | Sell | Sell | Sell | Sell | Sell | Sell | Sell |
| MCAP (MEur) | 7231.7 | 5542.3 | 6037.7 | 8983.2 | 11064.9 | 11064.9 | 11064.9 |
| Price | 51.24 | 39.27 | 42.78 | 63.65 | 78.4 | 78.4 | 78.4 |
| EV | 7113.0 | 5636.0 | 6159.0 | 9128.0 | 10817.0 | 10282.0 | 9659.0 |
| P/S | 6.5 | 4.66 | 3.91 | 4.75 | 5.59 | 5.32 | 4.49 |
| EV/S | 6.4 | 4.74 | 3.99 | 4.83 | 5.47 | 4.95 | 3.92 |
| EV/EBIT | 33.94 | 20.13 | 14.61 | 14.45 | 18.14 | 19.55 | 12.55 |
| P/E | 43.67 | 25.58 | 18.3 | 17.42 | 23.32 | 26.3 | 17.96 |
| P/B | 7.96 | 6.23 | 6.01 | 6.99 | 7.31 | 5.72 | 4.34 |
| P/OCF | 16.65 | 46.54 | 20.61 | 28.36 | 18.26 | 17.75 | 15.59 |
| EV/OCF | 16.37 | 47.32 | 21.02 | 28.82 | 17.85 | 16.5 | 13.61 |
| P/FCF | 25.82 | 517.97 | 29.06 | 41.19 | 21.13 | 20.66 | 17.78 |
| EV/FCF | 25.39 | 526.69 | 29.64 | 41.85 | 20.65 | 19.2 | 15.52 |
Income Statement
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Revenue | 1111.8 | 1189.7 | 1542.4 | 1889.6 | 1977.8 | 2078.9 | 2466.0 |
| Rev. Growth, % | 10.5 | 7.0 | 29.6 | 22.5 | 4.7 | 5.1 | 18.6 |
| Ebit | 209.6 | 279.9 | 421.5 | 631.6 | 596.3 | 525.8 | 770.0 |
| Ebit Growth, % | -19.6 | 33.5 | 50.6 | 49.8 | -5.6 | -11.8 | 46.4 |
| Ebit, % | 18.9 | 23.5 | 27.3 | 33.4 | 30.1 | 25.3 | 31.2 |
| Profit | 165.6 | 216.7 | 330.0 | 515.8 | 474.5 | 420.7 | 616.0 |
| EPS | 1.17 | 1.54 | 2.34 | 3.65 | 3.36 | 2.98 | 4.36 |
| Profit Growth, % | -19.7 | 30.9 | 52.3 | 56.3 | -8.0 | -11.3 | 46.4 |
| Profit, % | 14.9 | 18.2 | 21.4 | 27.3 | 24.0 | 20.2 | 25.0 |
Balance Sheet
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Inventory | 315.6 | 362.2 | 418.6 | 456.3 | 534.9 | 592.3 | 669.8 |
| Acc. Receivable | 180.7 | 247.1 | 254.9 | 352.3 | 306.5 | 322.6 | 349.7 |
| Cash | 332.6 | 106.7 | 205.6 | 160.9 | 380.5 | 916.1 | 1538.3 |
| Equity | 908.1 | 890.1 | 1005.0 | 1284.5 | 1512.8 | 1933.5 | 2549.5 |
| ROE, % | 18.2 | 24.3 | 32.8 | 40.2 | 31.4 | 21.8 | 24.2 |
| ROCE, % | 18.7 | 25.7 | 31.6 | 39.7 | 36.2 | 25.4 | 28.7 |
| Net Debt | -118.7 | 93.3 | 121.6 | 144.4 | -247.7 | -783.3 | -1405.6 |
| Gearing, % | -13.1 | 10.5 | 12.1 | 11.2 | -16.4 | -40.5 | -55.1 |
| Equity ratio, % | 60.4 | 61.9 | 61.7 | 63.9 | 70.5 | 79.0 | 90.0 |
| Acc. Payable | 114.4 | 102.3 | 87.1 | 123.5 | 122.4 | 104.7 | 80.1 |
| Total Assets | 1503.6 | 1438.6 | 1629.1 | 2009.8 | 2147.3 | 2447.8 | 2833.2 |
| ROA, % | 11.0 | 15.1 | 20.3 | 25.7 | 22.1 | 17.2 | 21.7 |
Cash Flow
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 434.4 | 119.1 | 293.0 | 316.7 | 605.9 | 623.2 | 709.8 |
| Investment Cash Flow | -154.3 | -108.4 | -85.2 | -98.6 | -82.1 | -87.6 | -87.6 |
| Free Cash Flow | 280.1 | 10.7 | 207.8 | 218.1 | 523.8 | 535.6 | 622.2 |
| OCF/CAPEX | 2.82 | 1.1 | 3.44 | 3.21 | 7.38 | 7.11 | 8.1 |
| Financial Cash Flow | -82.4 | -243.3 | -108.8 | -263.6 | -304.3 | 0.0 | 0.0 |
Disclaimer
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
The data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.
Contact: quant@quantfactory.eu